Paratek Pharmaceuticals, Inc. (PRTK): Price and Financial Metrics


Paratek Pharmaceuticals, Inc. (PRTK): $4.77

0.02 (+0.42%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PRTK to Watchlist
Sign Up

Industry: Biotech


Ranked

of 503

in industry

PRTK POWR Grades


  • PRTK scores best on the Value dimension, with a Value rank ahead of 81.26% of US stocks.
  • PRTK's strongest trending metric is Momentum; it's been moving down over the last 48 weeks.
  • PRTK ranks lowest in Momentum; there it ranks in the 4th percentile.

PRTK Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for PRTK is -1.04 -- better than only 4.05% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -1.78 for Paratek Pharmaceuticals Inc; that's greater than it is for just 4.42% of US stocks.
  • As for revenue growth, note that PRTK's revenue has grown 243.65% over the past 12 months; that beats the revenue growth of 96.9% of US companies in our set.
  • Stocks that are quantitatively similar to PRTK, based on their financial statements, market capitalization, and price volatility, are RDHL, CNTG, FCEL, SNES, and APDN.
  • PRTK's SEC filings can be seen here. And to visit Paratek Pharmaceuticals Inc's official web site, go to paratekpharma.com.

PRTK Valuation Summary

  • PRTK's EV/EBIT ratio is -12.7; this is 143.34% lower than that of the median Healthcare stock.
  • Over the past 153 months, PRTK's price/sales ratio has gone up 2.3.
  • PRTK's EV/EBIT ratio has moved down 13.1 over the prior 153 months.

Below are key valuation metrics over time for PRTK.

Stock Date P/S P/B P/E EV/EBIT
PRTK 2021-08-31 2.6 -2.7 -5.0 -12.7
PRTK 2021-08-30 2.6 -2.7 -5.0 -12.7
PRTK 2021-08-27 2.6 -2.7 -5.0 -12.7
PRTK 2021-08-26 2.5 -2.6 -4.8 -12.5
PRTK 2021-08-25 2.6 -2.7 -4.9 -12.6
PRTK 2021-08-24 2.6 -2.7 -4.9 -12.6

PRTK Growth Metrics

  • Its 5 year revenue growth rate is now at 576.51%.
  • Its 2 year price growth rate is now at -58.75%.
  • Its year over year revenue growth rate is now at 142.43%.
PRTK's revenue has moved up $98,427,000 over the prior 33 months.

The table below shows PRTK's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 103.599 -107.493 -54.494
2021-03-31 55.433 -94.616 -87.27
2020-12-31 46.924 -103.424 -96.541
2020-09-30 39.872 -115.104 -98.896
2020-06-30 30.147 -114.35 -110.655
2020-03-31 22.866 -128.615 -120.797

PRTK's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PRTK has a Quality Grade of D, ranking ahead of 18.86% of graded US stocks.
  • PRTK's asset turnover comes in at 0.58 -- ranking 61st of 677 Pharmaceutical Products stocks.
  • BHVN, EVFM, and IBRX are the stocks whose asset turnover ratios are most correlated with PRTK.

The table below shows PRTK's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.580 0.831 -0.114
2021-03-31 0.291 0.821 -0.222
2020-12-31 0.224 0.816 -0.242
2020-09-30 0.175 0.812 -0.234
2020-06-30 0.125 0.787 -0.259
2020-03-31 0.090 0.792 -0.276

PRTK Price Target

For more insight on analysts targets of PRTK, see our PRTK price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $21.75 Average Broker Recommendation 1.25 (Strong Buy)

PRTK Stock Price Chart Interactive Chart >

Price chart for PRTK

PRTK Price/Volume Stats

Current price $4.77 52-week high $11.23
Prev. close $4.75 52-week low $4.51
Day low $4.72 Volume 269,600
Day high $4.90 Avg. volume 494,565
50-day MA $5.40 Dividend yield N/A
200-day MA $6.96 Market Cap 232.75M

Paratek Pharmaceuticals, Inc. (PRTK) Company Bio


Paratek Pharmaceuticals focuses on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry in the United States. The company was founded in 1996 and is based in in Boston, Massachusetts.


PRTK Latest News Stream


Event/Time News Detail
Loading, please wait...

PRTK Latest Social Stream


Loading social stream, please wait...

View Full PRTK Social Stream

Latest PRTK News From Around the Web

Below are the latest news stories about Paratek Pharmaceuticals Inc that investors may wish to consider to help them evaluate PRTK as an investment opportunity.

Paratek Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference

BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that Randy Brenner, Chief Development and Regulatory Officer, will present at the H.C. Wainwright 23 rd Annual Global Investment (Virtual) Conference. The on-demand presentation will be available on September 13 at 7:00 a.m. ET.

Intrado Digital Media | September 9, 2021

Paratek Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference

BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that Randy Brenner, Chief Development and Regulatory Officer, will present at the H.C. Wainwright 23rd Annual Global Investment (Virtual) Conference. The on-demand pr

Yahoo | September 9, 2021

Paratek's (PRTK) Nuzyra Gets FDA's Orphan Drug Tag for NTM

The FDA bestows an Orphan Drug designation to Paratek's (PRTK) marketed drug Nuzyra for the treatment of infections caused by Nontuberculous Mycobacteria.

Yahoo | August 19, 2021

The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV) Alkermes plc (NASDAQ: ALKS) Bio-Rad Laboratories, Inc. (NYSE: BIO) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) Gilead Sciences, Inc. (NASDAQ: GILD) GlaxoSmithKline plc (NYSE: GSK) (announced FDA approval for label expansion for its Jemperli) Novo Nordisk A/S (NYSE: NVO) Innoviva, Inc. (NASDAQ: INVA) Intuitive Surgical, Inc.

Yahoo | August 19, 2021

Paratek's Antibiotic Gets FDA Orphan Drug Tag For Lung Infection

The FDA has granted Orphan Drug Designation to Paratek Pharmaceuticals Inc's (NASDAQ: PRTK), Nuzyra (omadacycline) for infections caused by Nontuberculous Mycobacteria (NTM). The orphan drug designation includes NTM pulmonary disease caused by Mycobacterium abscessus complex (MABc), currently in an ongoing Phase 2b study initiated by Paratek. Nuzyra is a once-daily, broad-spectrum antibiotic currently approved for acute bacterial skin and skin structure infections and community-acquired bacteria

Yahoo | August 19, 2021

Read More 'PRTK' Stories Here

PRTK Price Returns

1-mo -5.17%
3-mo -34.57%
6-mo -34.39%
1-year -25.12%
3-year -50.57%
5-year -64.93%
YTD -23.80%
2020 55.33%
2019 -21.44%
2018 -71.34%
2017 16.23%
2016 -18.82%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 6.0699 seconds.